(Q45984342)

English

Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study.

scientific article published in July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

1 reference

based on heuristic

inferred from title

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

Kateřina Jarošová

object named as

Katerina Jarosova

2

0 references

author name string

Mark C Genovese

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

Dorota Cieślak

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

Jeffrey Alper

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

Alan Kivitz

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

Peter Maes

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

Lilia Pineda

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

Mindy Chen

9

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

Farrukh Zaidi

10

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

publication date

1 July 2015

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

67

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

1703-1710

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39120

21 January 2018

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FART.39120

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39120

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39120

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39120

21 January 2018

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

1 reference

https://api.crossref.org/works/10.1002%2FART.39120

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.39120

21 January 2018

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://api.crossref.org/works/10.1002%2FART.39120

21 January 2018

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FART.39120

21 January 2018

Identifiers

10.1002/ART.39120

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/25779750

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45984342&oldid=1509216210"